Company Overview

Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.

Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.

This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.

The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts.

Summary

The Executive Director, Commercial Strategy & Execution will lead strategic portfolio or country-level initiatives, drive launch readiness preparation for key markets, help develop and implement strategic and executional plans, optimize sales and marketing operations, and build / adopt commercial capabilities within key markets.

Your Role:

Lead and manage key portfolio or country-level initiatives for the CCO in collaboration with key Commercial functions related to key business priorities
Partner closely with cross-functional groups (e.g., Insights & Analytics, R&D, Market Access, Marketing / Sales, Regulatory Affairs, Finance, and Medical Affairs) for the development and implementation of strategic and executional plans
Continually monitor and analyze market, customer, and competitor trends, incorporating insights into commercial plans
Build launch excellence capabilities to ensure successful, coordinated and cross-functional launch preparations
Drive development of launch plans and tracking tools to advance portfolio commercialization efforts
Partner closely with all cross-functional groups and stakeholders across the company that are involved in Launch Readiness (e.g., Commercial teams, Supply Chain, Manufacturing, Finance, Regulatory Affairs, HR to drive launch preparation and ensure effective communication across the internal teams
Support Alliance Management team with leading and optimizing strategic collaborations by providing appropriate Commercial perspectives and direction to maximize value of global partnerships
Oversee critical initiatives to drive excellence in culture, operations and ways of working

What You Bring:

Bachelor's degree required
Life sciences, biotech, or pharma company professional with 15+ years of experience or equivalent work experience
Prior working experience within a pharma Commercial team and within Oncology
Strong working knowledge of legal landscape, FDA promotional regulations, standard operating procedures, and biotech development process required.
Excellent organizational, analytical, and communication skills
Ability to manage projects and changing priorities, multitask, and meet aggressive deadlines in a fast-paced environment.
Resourceful and driven, enthusiastic to collaborate with cross-functional teams and departments.
Ability to thrive in a dynamic and evolving environment, with a proactive and adaptable mindset to navigate change and drive continuous improvement

#LI-Hybrid

We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.

Salary range

$271,200—$406,800 USD

Salary range 271200 - 406800 USD

About the company

Tango Therapeutics develops cancer medicines by leveraging synthetic lethality to selectively kill cancer cells while sparing healthy cells. Its approach focuses on creating drugs that exploit interactions between gene pairs, aiming for targeted therapies that spare normal tissue. The company advances its treatments through a strong R&D program and collaborates with larger pharmaceutical partners, such as Gilead Sciences, to co-develop therapies and accelerate commercialization. Revenue comes from these partnerships and funding rounds like its Series B. Tango differentiates itself with a dedicated emphasis on genetically targeted cancer therapies, a robust pipeline, and leadership that guides strategic collaborations. The company’s goal is to bring next-generation, genetically targeted immunotherapies to market, improving outcomes for cancer patients by precisely targeting tumor biology.

Company Size

51-200

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2017

Get referred to Tango Therapeutics

See people who can refer or advise you

Simplify's Take

What believers are saying

June 2026 pancreatic data produced 11 responses among 12 evaluable patients, attracting capital.
August 2026 board additions and chair transition strengthened commercialization governance.
Tango said August 2026 it started regulator talks for registrational Phase 3 planning.

What critics are saying

Q2 2026 collaboration revenue fell to zero after Gilead ended, removing external funding.
June 2026 offering raised $600 million, signaling heavy cash burn before commercialization.
Revolution Medicines won FDA approval for daraxonrasib on August 26, 2026, squeezing Tango's combo narrative.

What makes Tango Therapeutics unique

Tango targets MTAP-deleted cancers using synthetic lethality, led by vopimetostat.
June 2026 PDAC data showed 92% ORR with daraxonrasib and 90% six-month PFS.
Tango combines biomarker-selected PRMT5 inhibition with RAS inhibitors, narrowing competition to precision oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-6%

1 year growth

-6%

2 year growth

-5%

BioPharma Watch

Oct 16th, 2026

Tango Therapeutics to present updated vopimetostat + RAS(ON) combination data at European Society For Medical Oncology (ESMO) Congress 2026.

Tango Therapeutics to present updated vopimetostat + RAS(ON) combination data at European Society For Medical Oncology (ESMO) Congress 2026. Key Takeaway: Tango Therapeutics will present updated data from a Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib for treating MTAP deleted RAS mutant metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer at the ESMO Congress 2026. The presentation is scheduled for October 25, 2026, with abstracts available on October 19, 2026. The company will also host a webcast to discuss these findings. Market sentiment analysis. Positive factors. * Tango Therapeutics is presenting updated data at a significant oncology congress. * The study focuses on a promising combination therapy for difficult-to-treat cancers. * The company is committed to precision medicine and innovative cancer treatments. BiopharmaWatch analysis. From its catalyst data and publicly available data · not financial advice Best trade, last catalyst 120-day peak, hindsight Typical move average across 7 past catalysts Cash runway Minimal dilution risk Lead asset Phase 1 · PDAC BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the Company will present updated data from a Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) at the European Society For Medical Oncology (ESMO) Congress 2026, which will be held October 23-27, 2026 in Madrid, Spain. Abstracts will be available on the ESMO website on Monday, October 19, 2026,12:05 am CEST. The data cutoff in the abstract is as of April 3, 2026. The poster presentation will include updated data. Abstract accepted for poster presentation. Title: A Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic PDAC and NSCLC Abstract #: 3149P Presenter: Alexander I. Spira, MD, PhD, FACP (NEXT Oncology, Fairfax, United States of America) Date, Time: Sunday, October 25, 2026, 12:00 - 12:45 pm CEST PDAC Investor Webcast and Conference Call Information The Company will host a PDAC focused investor webcast to discuss these data at 7:30 am ET on Friday, October 23, 2026. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.tangotx.com. The webcast will be available for replay for at least 30 days on the Company website. Analysts who wish to join the teleconference and participate in Q&A should register here. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango Therapeutics leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com. Forward-Looking Statements Certain statements in this press release may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief, or current expectation of Tango Therapeutics. Forward-looking statements are not purely historical and may be accompanied by words such as "may", "should", "expect", "intend", "will", "goal", "estimate", "anticipate", "believe", "predict", "designed," "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. For example, implicit or explicit statements concerning the following include or constitute forward-looking statements: statements regarding: (i) the potential of the Company's PRMT5 molecules, as both standalone treatments and in combination with RAS(ON)-inhibitors; (ii) the Company's beliefs regarding the timing of upcoming clinical milestones and data disclosures and (iii) expectations regarding the anticipated benefits of the Company's molecules and product candidates. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango Therapeutics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the risks described in the Company's filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as well as other filings the Company makes with the SEC from time to time. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The Company specifically disclaims any duty to update these forward-looking statements. Investors: elizabeth hickin [email protected]. Media: 1AB amanda lazaro [email protected]. Frequently asked questions. What is the focus of Tango Therapeutics' presentation? The presentation focuses on updated data from a Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib. When will the ESMO Congress 2026 take place? The ESMO Congress 2026 will be held from October 23-27, 2026, in Madrid, Spain. Who will present the updated data? Dr. Alexander I. Spira from NEXT Oncology will present the updated data. How can investors access the webcast? Investors can access the webcast under the 'Events & Presentations' section on Tango's website.

GlobeNewswire

Oct 16th, 2026

Tango Therapeutics to present updated vopimetostat + RAS(ON) combination data at European Society For Medical Oncology (ESMO) Congress 2026.

Tango Therapeutics to present updated vopimetostat + RAS(ON) combination data at European Society For Medical Oncology (ESMO) Congress 2026. Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET. BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the Company will present updated data from a Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) at the European Society For Medical Oncology (ESMO) Congress 2026, which will be held October 23-27, 2026 in Madrid, Spain. Abstracts will be available on the ESMO website on Monday, October 19, 2026,12:05 am CEST. The data cutoff in the abstract is as of April 3, 2026. The poster presentation will include updated data. Abstract accepted for poster presentation Title: A Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic PDAC and NSCLC Abstract #: 3149P Presenter: Alexander I. Spira, MD, PhD, FACP (NEXT Oncology, Fairfax, United States of America) Date, Time: Sunday, October 25, 2026, 12:00 - 12:45 pm CEST PDAC Investor Webcast and Conference Call Information The Company will host a PDAC focused investor webcast to discuss these data at 7:30 am ET on Friday, October 23, 2026. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.tangotx.com. The webcast will be available for replay for at least 30 days on the Company website. Analysts who wish to join the teleconference and participate in Q&A should register here. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango Therapeutics leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com. Forward-Looking Statements Certain statements in this press release may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief, or current expectation of Tango Therapeutics. Forward-looking statements are not purely historical and may be accompanied by words such as "may", "should", "expect", "intend", "will", "goal", "estimate", "anticipate", "believe", "predict", "designed," "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. For example, implicit or explicit statements concerning the following include or constitute forward-looking statements: statements regarding: (i) the potential of the Company's PRMT5 molecules, as both standalone treatments and in combination with RAS(ON)-inhibitors; (ii) the Company's beliefs regarding the timing of upcoming clinical milestones and data disclosures and (iii) expectations regarding the anticipated benefits of the Company's molecules and product candidates. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango Therapeutics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the risks described in the Company's filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as well as other filings the Company makes with the SEC from time to time. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. The Company specifically disclaims any duty to update these forward-looking statements. Company Profile Tango Therapeutics, Inc. Industry: Pharmaceuticals & Biotechnology Website: https://tangotx.com Recommended reading.

GlobeNewswire

Sep 1st, 2026

Tango Therapeutics to participate in the 2026 Cantor Global Healthcare Conference.

Tango Therapeutics to participate in the 2026 Cantor Global Healthcare Conference. BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. (NASDAQ: TNGX) ("Tango Therapeutics" or the "Company") today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT. The live webcast will be available under the "Events & Presentations" tab on the "Investors" page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.

Yahoo Finance

Aug 12th, 2026

Tango Therapeutics loses 37 cents per share in Q2, missing estimates as R&D expenses rise 13%

Tango Therapeutics reported a second-quarter loss of 37 cents per share, missing the consensus estimate of a 31-cent loss. The company recorded no collaboration revenues, down from $3.2 million a year earlier, following the conclusion of its Gilead collaboration. Shares fell 4.8%. Research and development expenses rose 13% year-over-year to $37.2 million, driven by clinical programme advancement. General and administrative expenses nearly doubled to $22.6 million due to higher personnel costs. In June, Tango released positive data from a phase I/II study of lead candidate vopimetostat combined with Revolution Medicines' RAS(ON) inhibitors in pancreatic cancer patients. The combination achieved a 92% objective response rate and 90% six-month progression-free survival rate. The company plans to finalise a phase III study design later in 2026.

Tango Therapeutics, Inc.

Aug 6th, 2026

Tango Therapeutics announces Executive chair transition.

Tango Therapeutics announces Executive chair transition. Aug 06, 2026 BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) - Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Dr. Barbara Weber, the Executive Chairman of the Board of Directors of Tango Therapeutics, will be stepping down in connection with other pursuits. "I am proud with what we have achieved at Tango and am confident that the Company is extremely well positioned to build on those achievements," Dr. Weber said. "The Company is profoundly grateful to Dr. Weber for all that she has brought to it: vision, leadership, passion for Tango and its employees and commitment to the groundbreaking work we are doing," said Tango President Dr. Malte Peters. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. Forward-Looking Statements Certain statements in this press release may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including statements regarding Forward-looking statements are not purely historical and may be accompanied by words such as "may," "should," "expect," "intend," "plan," "will," "goal," "estimate," "anticipate," "believe," "predict," "designed," "potential" or "continue," or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond Tango's control, and actual results could differ materially from those expressed or implied by these statements. These risks and uncertainties include, among others, risks related to drug development, clinical trials, regulatory review and approval, commercialization, competition, financing and Tango's ability to execute its business strategy. Additional information concerning risks, uncertainties and assumptions can be found in Tango's filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in Tango's Annual Report on Form 10-K for the fiscal year ended December 31, 2025. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Tango specifically disclaims any duty to update these forward-looking statements. Investors: Elizabeth Hickin [email protected] Media: 1AB Amanda Lazaro [email protected]

Tango Therapeutics

Executive Director - Commercial Strategy & Execution

About the job